Advanced Filters
noise
Found 332 clinical trials
A Anne A.L Elsinghorst

International Leukemia Target Board

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. …

- 25 years of age All Phase N/A
M Melissa Hines, MD

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Human gene therapy products are designed to achieve therapeutic effect through genetic modifications of human cells using retroviral or lentiviral vectors, resulting in permanent or long-acting changes in the human body. With this genetic modification comes risk of undesirable adverse events. Due to this risk, the Food and Drug Administration …

years of age All Phase N/A
M Morten Ladekarl, MD, DMSci

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients …

18 years of age All Phase N/A

Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation

Donor specific anti-HLA antibody (DSA) is closely related not only to primary graft rejection (GR) after HLA-incompatible transplantation, but also to the occurrence of primary PGF. Desensitisation therapy can reduce the level of DSA in patients and decrease the incidence of PGF after transplantation. However, most studies at home and …

15 - 60 years of age All Phase N/A
M Miri Ne'eman, MD

Early Detection and Screening of Hematological Malignancies - SANGUINE

This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), non-Hodgkin aggressive lymphoma NHL [diffuse large B cell lymphoma (DLBCL), follicular …

18 years of age All Phase N/A
M Mareike Verbeek

Register of Blood Stem Cell Transplantation

Register of patients with blood stem cell transplantations (autologous, allogen).

18 years of age All Phase N/A
Z Zhen Song, MD

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected …

years of age All Phase N/A
B Beat Bornhauser, PhD

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized …

- 40 years of age All Phase N/A
L Larry Saltzman, MD

The Leukemia and Lymphoma Society (LLS) National Research Registry

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

21 years of age All Phase N/A

Elderly CAncer Patient

The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age. Cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. The heterogeneity of …

70 years of age All Phase N/A

Simplify language using AI